Clinical Trial of Pulmonary Cryptococcosis in China

Multi-center Clinical Trial of Pulmonary Cryptococcosis in China

NCT02503449•Zhixin Liang

Summary

The purpose of the study:1.Improve the understanding of the risk factors of pulmonary cryptococcosis;2.Improve the awareness of pulmonary cryptococcosis clinical and imaging manifestations;3.Grasp pulmonary cryptococcosis patients of clinical and imaging manifestations in different conditions;4.Learn about antibacterial activity of antifungal drugs for cryptococcosis in China.

Detailed Description

1. Patients corresponding to inclusion criteria and obtaining informed consent are included in the research in department of respiration ward in cooperative hospitals. 2. Relevant case report forms are created in this study. 3. Basic information such as age,weight and height is recorded in selected cases.Clinical manifestations,risk factors,laboratory examination,imaging examination,etiological examination and histopathological examination are also recorded in selected cases by case report forms.In addition,antifungal treatment is recorded including name,dose,time of starting treatment and terminate treatment.Causes of terminate treatment and curative effect evaluation should be analysed. 4. Statistical analysis.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients possess clinical or imaging manifestations of pulmonary infections,with any of the results(by one of following conditions) by microbiological examination or histopathologic examination
•1. Cryptococcal capsular polysaccharide antigen of blood or pleural effusion is positive
•2. Cryptococcus（fungus culture) is discovered by lower respiratory tract specimens
•3. Cryptococcus（pleural effusions culture) is discovered by pleural effusions collected under sterile condition
•4. Cryptococcus（pus culture) is discovered by pus smear out of pulmonary infections in disseminated infection patients
•5. Cryptococcus（blood culture) is discovered by microscopy of specimens of blood smear
•6. Cryptococcus is discovered by culturing of the pathological tissue specimens in aseptic condition
•7. Cryptococcal capsular budding yeast with inflammatory reaction is discovered by histopathological examination,cell pathology examination or microscopic examination in aseptic condition

Exclusion Criteria

•1. Patients suffer from acquired immune deficiency syndrome
•2. Patients or their legal guardians request to withdraw the clinical research

Key Dates

Start Date

December 1, 2014

Primary Completion Date

December 1, 2016

Completion Date

December 1, 2017

Last Updated

July 21, 2015

Enrollment

260

ACTUAL participants

Conditions

Cryptococcosis

Cryptococcal Antigen Screening Plus Sertraline

NCT03002012

CryptococcosisCryptococcal Infections+1 more

View study

COMPLETEDPHASE4

Operational Research for Cryptococcal Antigen Screening

NCT01535469

Cryptococcal MeningitisCryptococcus Neoformans+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 21, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions